The 25th Annual Simcyp Consortium Meeting

Every year, the Consortium—comprising over 30 leading biopharmaceutical companies—convenes to discuss Physiologically Based Pharmacokinetic (PBPK) initiatives in drug development and their regulatory impacts. Consortium members collaborate closely with Simcyp scientists, guiding the scientific evolution of the Simcyp Simulator—a powerful platform utilized by prominent regulators such as the US FDA, EMA, Health Canada, and PMDA.

日程： 24th – 26th September 2024
会場： Radisson Hotel & Conference Centre London, Heathrow

Event Overview

Day 1: Tuesday, 24th September

Simcyp Open Day Celebration

Join us for a day dedicated to the Simcyp concept. The evening includes a drinks reception.

開催時間： 9:00 AM – 6:00 PM

OPEN TO ALL: Academic, regulatory associates, and Simcyp Consortium members are welcome.

For the first time in history of the Simcyp Consortium, non-members are invited to our “Open Day”. This is a unique opportunity to connect with industry leaders, regulatory experts, and academics as we reflect on and celebrate Simcyp’s remarkable 25-year journey prior to the start of the Consortium meeting.

Event Highlights:

History of the Consortium: Explore its impact on Drug-Drug Interaction Predictions.
Simcyp PBPK Modeling Impact: Discover its influence on drug development, regulatory sciences, biopharmaceutics, and special populations.

Key Highlights:

Session 1 Simcyp Consortium History and its impact on Drug-Drug Interaction Predictions
Session 2 Simcyp PBPK modelling impact on drug development and regulatory sciences
Session 3 Simcyp PBPK modelling impact on biopharmaceutics and special populations
Session 4 Simcyp Consortium members perspective and future directions

Agenda:

開催時間	講演者	Title
09:00	Masoud Jamei	Welcome Remarks
	Session 1 Chair: Iain Gardner	Simcyp Consortium History and its impact on Drug-Drug Interaction Predictions
09:05	Amin Rostami	Simcyp Vision 25 Years on!
09:45	Loeckie De Zwart	Evolving role of in vitro data in PBPK modelling and how PBPK modelling informed in vitro data generation and analysis
10:15	Gemma Dickinson	Simcyp and predicting DDI
10:45	Refreshment Break
	Session 2 Chair: Karen R Yeo	Simcyp PBPK modelling impact on drug development and regulatory sciences
11:15	Yuching Yang	Impact of PBPK on regulatory sciences
11:45	Ping Zhao	Impact of PBPK on Global Health
12:15	Lunch Break
	Session 3 Chair: Amin Rostami	Simcyp PBPK modelling impact on clinical pharmacology, biopharmaceutics and special populations
13:15	Saskia de Wildt	Impact of Simcyp on Development of new Generation of Scientists
13:45	Kunal Taskar	Impacts of the Simcyp on Clinical Pharmacology within Pharma
14:15	TBC	Potential Impacts of PBPK modelling on personalised dosing
14:45	Mark McAllister	Simcyp contributions to PBPK modelling in biopharmaceutics
15:15	Refreshment Break
	Session 4 Chair: Masoud Jamei	Simcyp Consortium perspective and future directions
15:45	Kunal Tasker	Consortium Members Perspective
16:15	TBC	Round table discussion: What future holds for PBPK and Simcyp Consortium?
16:50	Rob Aspbury	Concluding Remarks
17:00	End of the meeting
18:00	Drinks Reception, Buffet Dinner & Poster Viewing